At the WFH 2014 World Congress in Melbourne, WFH president Alain Weill announced the donation of more than 700 million IUs of factor from corporations that have answered the WFH global call to action that was first given at the 2012 World Congress in Paris.
These generous contributions have made the WFH the world’s largest supply channel for donated hemophilia products. Since 1994, WFH’s Humanitarian Aid Program has distributed 248 million IUs of product in 86 countries, helping about 90,000 people with bleeding disorders.
And yet, said WFH president Alain Weill during Monday’s plenary session, 75 per cent of people around the world who have bleeding disorders still don’t receive appropriate care.
Thanks to the generosity of corporate partners and, in a particular, a new, groundbreaking agreement with Biogen Idec and Sobi, that number may soon decrease.
On May 13, Weill announced that these manufacturers have agreed to donate 500 million IUs of factor VIII and factor IX over the next five years to WFH’s Humanitarian Aid Program. “That’s 500 million IUs of prolonged half-life treatment products,” Weill said.
Biogen Idec and Sobi join two other manufacturers that made significant, multi-year treatment product donations that same month: CSL Behring and Grifols.
In 2009, CSL Behring was the first WHF partner to commit to annual donations, and it has renewed its agreement for another three years. Grifols has also made a three-year commitment to deliver 60 million IUs of product.
Sobi CEO Geoffrey McDonough said his company made its donation both to increase the amount of product available and to ensure a more consistent supply.
In the long run, said Biogen Idec CEO George A. Scangos, PhD, “our sincere hope is that this initiative will inspire others to step up their donations as well.”
The first vials of the new product from Biogen Idec will be available for shipment in the second half of 2015.